Abstract
We have identified desmoglein-2 (DSG-2) as the primary high-affinity receptor used by adenoviruses Ad3, Ad7, Ad11 and Ad14. These serotypes represent key human pathogens causing respiratory and urinary tract infections. In epithelial cells, adenovirus binding of DSG-2 triggers events reminiscent of epithelial-to-mesenchymal transition, leading to transient opening of intercellular junctions. This opening improves access to receptors, for example, CD46 and Her2/neu, that are trapped in intercellular junctions. In addition to complete virions, dodecahedral particles (PtDds), formed by excess amounts of viral capsid proteins, penton base and fiber during viral replication, can trigger DSG-2–mediated opening of intercellular junctions as shown by studies with recombinant Ad3 PtDds. Our findings shed light on adenovirus biology and pathogenesis and may have implications for cancer therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
References
Bergelson, J.M. et al. Isolation of a common receptor for coxsackie B viruses and adenoviruses 2 and 5. Science 275, 1320–1323 (1997).
Tuve, S. et al. A new group B adenovirus receptor is expressed at high levels on human stem and tumor cells. J. Virol. 80, 12109–12120 (2006).
Louie, J.K. et al. Severe pneumonia due to adenovirus serotype 14: a new respiratory threat? Clin. Infect. Dis. 46, 421–425 (2008).
Tate, J.E. et al. Outbreak of severe respiratory disease associated with emergent human adenovirus serotype 14 at a US air force training facility in 2007. J. Infect. Dis. 199, 1419–1426 (2009).
Wang, H., Tuve, S., Erdman, D.D. & Lieber, A. Receptor usage of a newly emergent adenovirus type 14. Virology 387, 436–441 (2009).
Yamamoto, M. & Curiel, D.T. Current issues and future directions of oncolytic adenoviruses. Mol. Ther. 18, 243–250 (2010).
Turley, E.A., Veiseh, M., Radisky, D.C. & Bissell, M.J. Mechanisms of disease: epithelial-mesenchymal transition—does cellular plasticity fuel neoplastic progression? Nat. Clin. Pract. Oncol. 5, 280–290 (2008).
Strauss, R. et al. Epithelial phenotype confers resistance of ovarian cancer cells to oncolytic adenoviruses. Cancer Res. 69, 5115–5125 (2009).
Coyne, C.B. & Bergelson, J.M. CAR: a virus receptor within the tight junction. Adv. Drug Deliv. Rev. 57, 869–882 (2005).
Thiery, J.P. & Sleeman, J.P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell Biol. 7, 131–142 (2006).
Norrby, E., Nyberg, B., Skaaret, P. & Lengyel, A. Separation and characterization of soluble adenovirus type 9 components. J. Virol. 1, 1101–1108 (1967).
Fuschiotti, P. et al. Structure of the dodecahedral penton particle from human adenovirus type 3. J. Mol. Biol. 356, 510–520 (2006).
Fender, P., Boussaid, A., Mezin, P. & Chroboczek, J. Synthesis, cellular localization and quantification of penton-dodecahedron in serotype 3 adenovirus–infected cells. Virology 340, 167–173 (2005).
Di Guilmi, A.M., Barge, A., Kitts, P., Gout, E. & Chroboczek, J. Human adenovirus serotype 3 (Ad3) and the Ad3 fiber protein bind to a 130-kDa membrane protein on HeLa cells. Virus Res. 38, 71–81 (1995).
Fleischli, C. et al. Species B adenovirus serotypes 3, 7, 11 and 35 share similar binding sites on the membrane cofactor protein CD46 receptor. J. Gen. Virol. 88, 2925–2934 (2007).
Short, J.J. et al. Adenovirus serotype 3 utilizes CD80 (B7.1) and CD86 (B7.2) as cellular attachment receptors. Virology 322, 349–359 (2004).
Short, J.J., Vasu, C., Holterman, M.J., Curiel, D.T. & Pereboev, A. Members of adenovirus species B utilize CD80 and CD86 as cellular attachment receptors. Virus Res. 122, 144–153 (2006).
Sirena, D. et al. The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J. Virol. 78, 4454–4462 (2004).
Gaggar, A., Shayakhmetov, D.M. & Lieber, A. CD46 is a cellular receptor for group B adenoviruses. Nat. Med. 9, 1408–1412 (2003).
Marttila, M. et al. CD46 is a cellular receptor for all species B adenoviruses except types 3 and 7. J. Virol. 79, 14429–14436 (2005).
Segerman, A., Arnberg, N., Erikson, A., Lindman, K. & Wadell, G. There are two different species B adenovirus receptors: sBAR, common to species B1 and B2 adenoviruses, and sB2AR, exclusively used by species B2 adenoviruses. J. Virol. 77, 1157–1162 (2003).
Gustafsson, D.J., Segerman, A., Lindman, K., Mei, Y.F. & Wadell, G. The Arg279Gln substitution in the adenovirus type 11p (Ad11p) fiber knob abolishes EDTA-resistant binding to A549 and CHO-CD46 cells, converting the phenotype to that of Ad7p. J. Virol. 80, 1897–1905 (2006).
Persson, B.D. et al. An arginine switch in the species B adenovirus knob determines high-affinity engagement of the cellular receptor CD46. J. Virol. 83, 673–686 (2009).
Chitaev, N.A. & Troyanovsky, S.M. Direct Ca2+-dependent heterophilic interaction between desmosomal cadherins, desmoglein and desmocollin, contributes to cell-cell adhesion. J. Cell Biol. 138, 193–201 (1997).
Cowin, P. Unraveling the cytoplasmic interactions of the cadherin superfamily. Proc. Natl. Acad. Sci. USA 91, 10759–10761 (1994).
Biedermann, K. et al. Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. J. Pathol. 207, 199–206 (2005).
Harada, H., Iwatsuki, K., Ohtsuka, M., Han, G.W. & Kaneko, F. Abnormal desmoglein expression by squamous cell carcinoma cells. Acta Derm. Venereol. 76, 417–420 (1996).
Schmitt, C.J. et al. Homo- and heterotypic cell contacts in malignant melanoma cells and desmoglein 2 as a novel solitary surface glycoprotein. J. Invest. Dermatol. 127, 2191–2206 (2007).
Trojan, L. et al. Identification of metastasis-associated genes in prostate cancer by genetic profiling of human prostate cancer cell lines. Anticancer Res. 25, 183–191 (2005).
Abbod, M.F., Hamdy, F.C., Linkens, D.A. & Catto, J.W. Predictive modeling in cancer: where systems biology meets the stock market. Expert Rev. Anticancer Ther. 9, 867–870 (2009).
Leopold, P.L. & Crystal, R.G. Intracellular trafficking of adenovirus: many means to many ends. Adv. Drug Deliv. Rev. 59, 810–821 (2007).
Tuve, S. et al. Role of cellular heparan sulfate proteoglycans in infection of human adenovirus serotype 3 and 35. PLoS Pathog. 4, e1000189 (2008).
Fender, P., Ruigrok, R.W., Gout, E., Buffet, S. & Chroboczek, J. Adenovirus dodecahedron, a new vector for human gene transfer. Nat. Biotechnol. 15, 52–56 (1997).
Gao, W., Robbins, P.D. & Gambotto, A. Human adenovirus type 35: nucleotide sequence and vector development. Gene Ther. 10, 1941–1949 (2003).
Wang, H. et al. In vitro and in vivo properties of adenovirus vectors with increased affinity to CD46. J. Virol. 82, 10567–10579 (2008).
Nava, P. et al. Desmoglein-2: a novel regulator of apoptosis in the intestinal epithelium. Mol. Biol. Cell 18, 4565–4578 (2007).
Kowalczyk, A.P. et al. Structure and function of desmosomal transmembrane core and plaque molecules. Biophys. Chem. 50, 97–112 (1994).
Getsios, S., Huen, A.C. & Green, K.J. Working out the strength and flexibility of desmosomes. Nat. Rev. Mol. Cell Biol. 5, 271–281 (2004).
Wang, H. et al. A recombinant adenovirus type 35 fiber knob protein sensitizes lymphoma cells to rituximab therapy. Blood 115, 592–600 (2010).
Khatri, P. et al. New onto-tools: Promoter-Express, nsSNPCounter and Onto-Translate. Nucleic Acids Res. 34, W626–W631 (2006).
Bostrom, J. et al. Variants of the antibody herceptin that interact with HER2 and VEGF at the antigen binding site. Science 323, 1610–1614 (2009).
Walters, R.W. et al. Adenovirus fiber disrupts CAR-mediated intercellular adhesion allowing virus escape. Cell 110, 789–799 (2002).
Coyne, C.B., Shen, L., Turner, J.R. & Bergelson, J.M. Coxsackievirus entry across epithelial tight junctions requires occludin and the small GTPases Rab34 and Rab5. Cell Host Microbe 2, 181–192 (2007).
Schlegel, N. et al. Desmoglein 2–mediated adhesion is required for intestinal epithelial barrier integrity. Am. J. Physiol. Gastrointest. Liver Physiol. 298, G774–G783 (2010).
Mahoney, M.G., Simpson, A., Aho, S., Uitto, J. & Pulkkinen, L. Interspecies conservation and differential expression of mouse desmoglein gene family. Exp. Dermatol. 11, 115–125 (2002).
Schäfer, S., Koch, P.J. & Franke, W.W. Identification of the ubiquitous human desmoglein, Dsg2, and the expression catalogue of the desmoglein subfamily of desmosomal cadherins. Exp. Cell Res. 211, 391–399 (1994).
Green, S.K., Karlsson, M.C., Ravetch, J.V. & Kerbel, R.S. Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. Cancer Res. 62, 6891–6900 (2002).
Wang, H. et al. Identification of CD46 binding sites within the adenovirus serotype 35 fiber knob. J. Virol. 81, 12785–12792 (2007).
Keim, S.A., Johnson, K.R., Wheelock, M.J. & Wahl, J.K. III. Generation and characterization of monoclonal antibodies against the proregion of human desmoglein-2. Hybridoma (Larchmt) 27, 249–258 (2008).
Shayakhmetov, D.M., Papayannopoulou, T., Stamatoyannopoulos, G. & Lieber, A. Efficient gene transfer into human CD34+ cells by a retargeted adenovirus vector. J. Virol. 74, 2567–2583 (2000).
Gaggar, A., Shayakhmetov, D. & Lieber, A. Identifying functional adenovirus-host interactions using tandem mass spectrometry. Methods Mol. Med. 131, 141–155 (2007).
Seppen, J., Barry, S.C., Harder, B. & Osborne, W.R. Lentivirus administration to rat muscle provides efficient sustained expression of erythropoietin. Blood 98, 594–596 (2001).
Li, Z. et al. Toward a stem cell gene therapy for breast cancer. Blood 113, 5423–5433 (2009).
Tuve, S. et al. Combination of tumor site-located CTL-associated antigen-4 blockade and systemic regulatory T-cell depletion induces tumor-destructive immune responses. Cancer Res. 67, 5929–5939 (2007).
Acknowledgements
This work was supported by US National Institutes of Health grants R01 CA080192 and R01 HLA078836 and Pacific Ovarian Cancer Research Consortium/Specialized Program of Research Excellence in Ovarian Cancer Grant P50 CA83636. We thank R. van Rensburg for critical comments and the Functional Genomics Core at the Center for Ecogenetics and Environmental Health, School of Public Health University of Washington for array analysis.
Author information
Authors and Affiliations
Contributions
H.W. conducted the studies for the identification and validation of DSG-2 as an adenovirus receptor; Z.-Y.L. performed the immunofluorescence studies; Y.L. performed the in vivo studies; J.P. contributed to adenovirus attachment assays; I.B. contributed to in vivo studies; T.M. helped with the expression array studies; D.K. and M.R.D. participated in in vitro studies with Herceptin; R.S. performed the western blot studies for kinase activation; X.-B.Z. produced the DSG-2–expressing lentivirus vector; J.K.W. III provided the DSG-2–specific antibodies; N.U. and C.D. provided tumor biopsies; A.H. helped with data interpretation; P.F. performed the Biacore studies and provided recombinant PtDds, and A.L. supervised the project and wrote the manuscript.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–7 and Supplementary Methods (PDF 1106 kb)
Rights and permissions
About this article
Cite this article
Wang, H., Li, ZY., Liu, Y. et al. Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat Med 17, 96–104 (2011). https://doi.org/10.1038/nm.2270
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm.2270
This article is cited by
-
Broad sialic acid usage amongst species D human adenovirus
npj Viruses (2023)
-
Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy
Drug Delivery and Translational Research (2023)
-
Translational development of a tumor junction opening technology
Scientific Reports (2022)
-
Identification of Desmoglein-2 as a novel target of Helicobacter pylori HtrA in epithelial cells
Cell Communication and Signaling (2021)
-
Understanding and addressing barriers to successful adenovirus-based virotherapy for ovarian cancer
Cancer Gene Therapy (2021)